NS
CRSP icon

NBC Securities’s CRISPR Therapeutics CRSP Stock Holding History

NBC Securities’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$70 – 2617
2025
Q4 		$70 Buy
+1
New +$60 ﹤0.01% 2754

Other funds holding CRSP

EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SC
Slow Capital Greenbrae, California $857M AUM 38.3% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
CIC
Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $900M AUM
BIP
Bouvel Investment Partners Phoenixville, Pennsylvania $442M AUM 70.77% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

NBC Securities's CRSP Position: Q2 2026 in Review

NBC Securities reduced its CRISPR Therapeutics (CRSP) stake by 5% in Q2 2026, selling an estimated $3.21K and leaving 1,150 shares worth $62.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1220.

NBC Securities first reported a position in CRSP in Q3 2023 and has held it in 12 quarters since. The position peaked at $76K in Q2 2025. 109 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • NBC Securities held 1,150 shares of CRISPR Therapeutics worth $62.7K as of Q2 2026.
  • NBC Securities sold 61 CRISPR Therapeutics shares in Q2 2026, an estimated $3.21K.
  • CRISPR Therapeutics made up ﹤0.01% of NBC Securities's portfolio in Q2 2026, its #1220 holding.
  • NBC Securities first reported a position in CRISPR Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • NBC Securities's CRISPR Therapeutics position peaked at $76K in Q2 2025.
  • 109 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on NBC Securities's 13F filing for Q2 2026, filed 21 Jul 2026.